摘要
新生血管性青光眼是一种难治性青光眼,其破坏性极强,失明率高,患者疼痛剧烈。常规抗青光眼方法难以奏效,既往临床上治疗方法较多,但效果都不甚理想。近年来随着玻璃体腔注射抗-VEGF药和青光眼引流钉等新技术的临床使用,联合使用包括改善视网膜缺血、抗新生血管生长和抗青光眼三个方面治疗新生血管性青光眼疗效有所改进,在治疗先后顺序上根据患者双眼的视功能情况采取更恰当的治疗策略可最大程度的保留患者残存视力,减低痛苦。本文依据近几年国内外文献对取得的相关研究进展进行简要综述。
As a kind of refractory glaucoma,the neovascular glaucoma causes severe pain and is extremely destructive with very high rate of blindness.Though there were a variety of clinical treatments to the neovascular glaucoma,their effects are very limited.With the application of new technology in recent years,many new kinds of treatment methods and strategies are applied in the clinic,such as anti-VEGF agents and glaucoma drainage devices,and the therapeutic effect is thus improved to some extent.Combined treatments can improve the efficacy from improving the blood supply for retina,anti-angiogenesis and anti-glaucoma.A more appropriate treatment coming with the individual situation of patients＇ visual acuity may help keep the remaining vision at the greatest extent,relieve the pain.Based on the literatures published at home and abroad during recent years,this paper gives a brief review on the advances in treatment of neovascular glaucoma.
出处
《国际眼科杂志》
CAS
2016年第3期462-465,共4页
International Eye Science
